Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Makes Pact With Neurosearch
by Lisa M. Jarvis
February 23, 2009
| A version of this story appeared in
Volume 87, Issue 8
Eli Lilly & Co. has teamed with the Scandanavian biotech firm NeuroSearch to develop new drugs based on NeuroSearch's novel ion-channel-modulation expertise. Over the course of the three-year pact, Lilly will hand over $13 million in up-front fees and research funding and make a $17 million investment in the company. NeuroSearch will be tasked with discovering ion-channel-modulating compounds to treat central nervous system disorders, and Lilly will have the option to license those compounds in exchange for further milestone and royalty payments upon their development and commercialization.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter